Comparison of $[^{18}\text{F}]$DCFPyL and $[^{68}\text{Ga}]$Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

Markus Dietlein, Carsten Kobe, Georg Kuhnert, Simone Stockter, Thomas Fischer, Klaus Schomäcker, Matthias Schmidt, Felix Dietlein, Boris D. Zlatopolskiy, Philipp Krapf, Raphael Richarz, Stephan Neubauer, Alexander Drzezga, Bernd Neumaier

1 Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
2 Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany
3 Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany
4 Western German Prostata Center, “Klinik am Ring”, Cologne, Germany

Abstract

Purpose: Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the $[^{68}\text{Ga}]$Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent prostate cancer. However, compared to Ga-68, a labeling with fluorine-18 (F-18) would offer advantages with respect to availability, production amount, and image resolution. $[^{18}\text{F}]$DCFPyL is a promising F-18-labeled candidate for PSMA-positron emission tomography (PET) imaging that has been recently introduced. In the current study, we aimed to compare $[^{68}\text{Ga}]$Ga-PSMA-HBED-CC and $[^{18}\text{F}]$DCFPyL for clinical use in biochemically relapsed prostate cancer.

Procedures: In 14 selected patients with PSA relapse of prostate cancer, $[^{18}\text{F}]$DCFPyL PET/X-ray computed tomography (CT) was performed in addition to $[^{68}\text{Ga}]$Ga-PSMA-HBED-CC PET/CT. A systematic comparison was carried out between results obtained with both tracers with regard to the number of detected PSMA-positive lesions, the standardized uptake value ($\text{SUV}_{\text{max}}$), and the lesion to background ratios.

Results: All suspicious lesions identified by $[^{68}\text{Ga}]$Ga-PSMA-HBED-CC were also detected with $[^{18}\text{F}]$DCFPyL. In three patients, additional lesions were observed using $[^{18}\text{F}]$DCFPyL PET/CT. The mean SUV$_{\text{max}}$ in the concordant $[^{18}\text{F}]$DCFPyL PSMA-positive lesions was significantly higher as compared to $[^{68}\text{Ga}]$Ga-PSMA-HBED-CC (14.5 vs. 12.2, $p=0.028, n=15$). The mean tumor to background ratios ($n=15$) were significantly higher for $[^{18}\text{F}]$DCFPyL compared to $[^{68}\text{Ga}]$Ga-PSMA-HBED-CC using kidney, spleen, or parotid as reference organs ($p=0.006, p=0.002, p=0.008$), but no significant differences were found using the liver ($p=0.167$) or the mediastinum ($p=0.363$) as reference organs.

Conclusion: $[^{18}\text{F}]$DCFPyL PET/CT provided a high image quality and visualized small prostate lesions with excellent sensitivity. $[^{18}\text{F}]$DCFPyL represents a highly promising alternative to $[^{68}\text{Ga}]$Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer.

Key words: Prostate-specific membrane antigen (PSMA), F-18, Ga-68, Positron emission tomography (PET), Prostate cancer
Introduction

The prostate-specific membrane antigen (PSMA) is overexpressed on the cell surface of prostate cancer (PC) cells [1]. Recent studies with gallium-68 (Ga-68)-labeled Glu-NH-CO-NH-Lys-(Ahx) ([68Ga]Ga-PSMA-HBED-CC) have shown the potential of this radioligand to detect relapses and metastases of PC with improved contrast when compared to [18F]fluoromethylcholine positron emission tomography (PET)/X-ray computed tomography (CT) [2–5]. Additionally, iodine-124, iodine-131, and lutetium-177-labeled PSMA ligands have been reported for dosimetric and therapeutic use [6, 7]. Several PSMA inhibitors were developed which compromise different pharmacophoric structures to interact with the binding pocket for N-acetyl-l-aspartyl-l-glutamate. PSMA-binding ligands are bound to the extracellular domain of PSMA. However, the transmembranous location of the binding domain and its enzyme activity enable the subsequent internalization of these ligands. The prostate-specific membrane antigen is also expressed in the tumor-associated neovascularization of gastric and colorectal cancer [8, 9]. Thus, these PSMA-selective ligands may be of interest for imaging other tumor types in the future.

In comparison to currently broadly applied Ga-68-labeled PSMA ligands, fluorine-18 (F-18)-labeled compounds would offer some important advantages. This includes not only an increase of the number of examinations owing to the higher production capacity but also an excellent image quality. The latter will be a result of optimized tracer doses leading to high imaging statistics and the decay properties of F-18 itself. F-18 exhibits a low positron emission energy of 0.6 MeV. Therefore, the distance to decelerate the positron in human tissue is much shorter in comparison to Ga-68 (β+-energy=2.3 MeV) resulting in a much higher image resolution. Recently, Chen and colleagues [10] have published first data on [18F]DCFPyL (2-(3-[[2-(2-carboxyethyl)-2-hydroxyphenyl] -methyl]-4-([6-18F]fluoro-pyridine-3-carboxyl-amino)-pentyl]-ureido)-pentanedioic acid), a new PSMA-selective ligand with a high binding affinity for PSMA. It was suggested that this compound may represent a highly promising candidate for PET imaging of PSMA-overexpressing tissues [10].

In this work, a comparison between [68Ga]Ga-PSMA-HBED-CC and [18F]DCFPyL PET/CT in patients with a PSA-relapse of prostate cancer was carried out.

We assumed that [18F]DCFPyL would bear the potential of high diagnostic accuracy due to the following:

- **Availability of higher tracer activity amounts in combination with the longer half-life of F-18, enabling imaging at later time points resulting in higher clearance and lower nonspecific binding**
- **Higher image quality due to lower positron emission energy of F-18**

We aimed to confirm and potentially extend the findings obtained with our diagnostic standard, [68Ga]Ga-PSMA-HBED-CC PET/CT, by adding a second scan with [18F]DCFPyL, representing a different PSMA tracer. By choosing this approach, we tried to collect accumulating evidence in the diagnostic assessment of selected patients and to compare the properties of [18F]DCFPyL with [68Ga]Ga-PSMA-HBED-CC at the same time.

Materials and Methods

Patient Characteristics

In this study, 14 selected patients were included who underwent both [68Ga]Ga-PSMA-HBED-CC PET/CT and [18F]DCFPyL PET/CT with the aim to determine if one of the two tracers exhibits better detection of recurrent prostate cancer and/or metastases. The patients had biochemical relapse of prostate cancer after initial curative treatment, either radical prostatectomy or radiation-based therapy. All patients showed rising PSA level and suspected progressive disease following prior treatment of prostate cancer. In 11 patients, the PSA level had increased to more than 1 ng/ml. All patients underwent the examination as part of their clinical workup. Patients were selected for the dual-scan procedure assuming that a thorough diagnostic assessment would have a significant influence on their individual subsequent therapeutic measures, i.e., local versus systemic therapy, indication for or exclusion from surgical treatment or external beam radiation therapy. This included, e.g., suspected false-negative or equivocal PET/CT results, detection of a solitary metastasis, or oligometastatic status potentially accessible for local therapy.

First, [68Ga]Ga-PSMA-HBED-CC PET/CT was performed, representing the standard procedure at our center. Subsequently, in 14 selected patients, additional [18F]DCFPyL PET/CT was carried out within a period of 3 weeks following the first scan. All patients underwent the examinations as part of the clinical workup in order to accumulate diagnostic evidence and potentially optimize their individual treatment. This study does not represent a systematic clinical trial, comparing the clinical value of two diagnostic instruments in a blinded fashion. All patients signed informed consent regarding the scientific evaluation of their data.

Preparation of [68Ga]Ga-PSMA-HBED-CC

[68Ga]Ga-PSMA-HBED-CC was produced according to the methods reported by Eder et al. [11] and Schäfer et al. [12]. The whole labeling procedure was carried out under good manufacturing practice (GMP) conditions. For labeling, a 68Ge/68Ga-generator (iThemba), distributed by IDB Holland BV (Baarle-Nassau, the Netherlands), was used. After fractionated elution with 5 ml 0.6 M HCl, 500 μl Ga-68 generator eluate were neutralized with 250 μl 2 M sodium acetate solution (in Ultrapur water, sterilized in 1 ml aliquots). Then, 500 μl (5 μg in water, Ultrapur, Merck, Darmstadt, Germany) of PSMA-HBED-CC (ABX, Radeberg, Germany; CA index name: 4,6,12,19-tetraazaadecosane-1,3,7-tricarboxylic acid, 22—[3-[[2-[[5-(2-carboxyethyl)-2-hydroxyphenyl] -methyl] (carboxymethyl) amino] ethyl] (carboxymethyl) amino] methyl]-4-
hydroxyphenyl]—5,13,20-trioxo-, (3S,7S)-, supplied as trifluoroacetate salt) were added and mixed vigorously. The reaction mixture was heated at 80 °C for 10 min. After 5 min cooling at room temperature (RT), the solution was diluted with 8.75 ml sterile isotonic saline. Two aliquots for quality controls (radiochemical purity and endotoxin testing) were withdrawn. Radiochemical purity was determined by reverse phase HPLC (WellChrom system, Knauer, Berlin, Germany) with a Knauer Hypersil ODS (4 mm) column. Endotoxin testing (LAL) was carried out on Endosafe MCS™ from Charles River (Ecullly, France) using their cartridges with a sensitivity of 5.0–0.05 EU/ml. Samples were checked for sterility by the Institute for Medical Microbiology, Immunology and Hygiene, University Hospital Cologne. Labeling provided [68Ga]Ga-PSMA-HBED-CC in high radiochemical purity (>98 %). The specific activity of [68Ga]Ga-PSMA-HBED-CC was 62 GBq/μmol.

In addition, the affinity-related IC50 values of the reaction mixtures of both labeling conditions were determined on the PSMA expressing cell line LNCaP. Indeed, both the RT-labeled fraction and the 95 °C-labeled fraction bound PSMA with identical affinities (IC50 values 27.4±1.3 and 24.8±1.2 nm, respectively) [13].

**Preparation of [18F]DCFPyL**

[18F]Fluoride was produced via the 18O (p,n)18F reaction by bombardment of enriched [18O] water with 16.5 MeV protons using a MC16 cyclotron (Scanitronix, Uppsala, Sweden) at the Max Planck Institute for Metabolism Research.

The synthesis of [18F]DCFPyL was performed under GMP conditions as previously reported by Chen et al. [10]. The radiolabeled product was analyzed using the following conditions: column: Chromolith SpeedROD®, 50×4.6 mm (Merck Millipore, Darmstadt, Germany); eluent: 5 % EtOH in 0.38 % H3PO4 (pH 2); flow rate: 3.0 ml/min; tR=2.2 min. The final product was formulated in a PBS solution (pH 4–6). The formulated solution of [18F]DCFPyL was tested for sterility and endotoxin content. Production under GMP conditions provided [18F]DCFPyL in reasonable radiochemical yields of 8–12 % and in high radiochemical purity (>98 %). The specific activity of [18F]DCFPyL amounted to 72 GBq/μmol.

The PSMA enzyme inhibition potency of compound 3 was determined with a modified Amplex Red glutamic acid assay after incubation with the cell lysates of LNCaP cell extracts in the presence of NAAG for 2 h at 37 °C. The enzyme inhibitory constant (Ki) for compound 3 was 1.1±0.1 nmol/l, comparable with that of ZJ-43, which was 1.4±0.2 nmol/l under same measurement conditions. ZJ-43 is a urea-based potent inhibitor of NAAG and is used as an internal reference in the assay.

**Imaging**

The mean dosage of 128.3 MBq±35.9 MBq [68Ga]Ga-PSMA-HBED-CC solution was injected as an intravenous bolus. Variation of the injected activity was caused by the variable elution efficiencies obtained during the lifetime of the 68Ge–68Ga radionuclide generator. The preparations contained 2.65 nmol PSMA ligand.

The mean dosage of 318.4 MBq±59.0 MBq [18F]DCFPyL complex solution was injected as an intravenous bolus. The variability of the injected dose of [18F]DCFPyL is explained by the available activity after the production of [18F]DCFPyL and by adaption to body weight. The preparations contained between 2.7 and 5.1 nmol (mean 4.0 nmol) PSMA ligand depending on the dosage of [18F]DCFPyL.

Patients fasted for at least 4 h prior to injection of [68Ga]Ga-PSMA-HBED-CC or [18F]DCFPyL. There were no adverse effects observed in any of the patients after injection of both tracers.

For both tracers, whole-body PET and a non-contrast-enhanced (low-dose) CT scan were performed on a Biograph 16 PET/CT scanner (Siemens, Erlangen, Germany) in eight patients and on a Biograph mCT 128 scanner (Siemens, Erlangen, Germany) in six patients 1 h post injection of the [68Ga]Ga-PSMA-HBED-CC and 2 h post injection of the [18F]DCFPyL, respectively. The time window between injection and start of data acquisition was chosen analogously to published data for [68Ga]Ga-PSMA-HBED-CC [2–5] and for [18F]DCFPyL [14]. Attenuation correction was performed using the low-dose non-enhanced CT data.

To ensure comparability between different PET/CT scanners, reconstruction was performed via an OSEM algorithm (4 iterations and 14 subsets), followed by an intrinsic 5-mm Gaussian filter in all directions for the Biograph 16 True Point (Siemens Medical Solutions), containing full-ring dedicated PET and 16-slice CT instrumentation. When using the Biograph mCT Flow-Edge 128 PET/CT system (Siemens Medical Solutions) with a 128-slice spiral CT, iterative reconstruction was performed using 4 iterations and 12 subsets by an intrinsic 5-mm Gaussian filter.

**Image Analysis**

Image analysis was performed using an appropriate workstation and software (Syngo TrueD, Siemens, Erlangen, Germany). Clinical PET/CT reading was performed by three experienced specialists from the department of nuclear medicine and from the department of radiology in consensus in a side-by-side analysis of the results obtained with both tracers. Lesions were visually interpreted as suspicious for local relapse, lymph node metastasis, bone metastasis, or visceral metastasis.

The standardized uptake value (SUVmax) was measured in up to three hottest lesions (as identified in the [68Ga]Ga-PSMA-HBED-CC scan) and their counterpart in the [18F]DCFPyL scan. Background SUVmean values were measured in a volume of interest (VOI) with 2 cm diameter in the liver, spleen, kidney, mediastinum, and parotid in all patients. For the calculation of mean values and to compare the SUVmax values of the lesions and their ratios, SPSS 22 was used.

**Results**

Patient characteristics are shown in Table 1.

**Presence of PSMA-Positive Lesions**

In 4 of the 14 patients (29 %), no PSMA-positive lesions were detected with either [68Ga]Ga-PSMA-HBED-CC or with [18F]DCFPyL. In 10 of 14 patients (71 %), at least one lesion suspicious for prostate cancer tissue was detected in [68Ga]Ga-PSMA-HBED-CC PET/CT imaging and in [18F]DCFPyL PET/CT imaging. In 3 patients, at least one
additional PSMA-positive lesion was detected with [18F]DCFPyL PET/CT as compared to the [68Ga]Ga-PSMA scan. Thus, all patients were classified accordingly with both tracers regarding the general presence of a PSMA-positive suspicious finding (yes/no). Eleven patients (79 %) would also have been classified consistently with both tracers regarding number and location of their lesions, and in 3 (21 %) of patients, additional lesions were detected with [18F]DCFPyL.

**Type and Location of Lesions**

With respect to the type/location of suspicious lesions, [68Ga]Ga-PSMA-HBED-CC PET/CT had detected 2 bone metastases, and [18F]DCFPyL PET/CT had detected 5 putative bone metastases. [68Ga]Ga-PSMA-HBED-CC PET/CT had detected 20 lymph node metastases, and [18F]DCFPyL PET/CT had detected 26 putative lymph node metastases. [68Ga]Ga-PSMA-HBED-CC PET/CT and [18F]DCFPyL PET/CT were suspicious for local relapse in 4 cases each.

The additional suspicious lesions detected with [18F]DCFPyL were found in the lumbar vertebra L2 in a patients with bone metastases in the left humerus and the right femur (patient 2), in a pelvic lymph node beyond the vena cava inferior in a patient with a concordant left iliac PSMA-positive lymph node metastasis (patient 7), and in mediastinal, left cervical, left supraclavicular, left axillary lymph nodes as well as in the thoracal vertebra Th3 and the

| No. | Age (years) | PSA (ng/ml) | [68Ga] dosage (MBq) | [18F] dosage (MBq) | Local PSMA + | Nodal PSMA + | Distant PSMA + | Therapeutic consequence | Verification |
|-----|-------------|-------------|---------------------|---------------------|-------------|-------------|-------------|-------------------------|--------------|
| 1   | 53          | 4.1         | 177                 | 350                 | 1           | 1           | 0           | Surgery                 | LN histologically confirmed. LR not confirmed by core biopsy |
| 2   | 74          | 4.7         | 138                 | 364                 | 0           | 0           | 2           | Systemic and RT of bone metastases | CT           |
| 3   | 86          | 2.1         | 139                 | 347                 | 1           | 0           | 0           | Core biopsy of prostate | n.a.         |
| 4   | 68          | n.a.        | 104                 | 411                 | 1           | 0           | 0           | Core biopsy of prostate | LR not confirmed by core biopsy |
| 5   | 82          | 50          | 139                 | 382                 | 0           | >10         | 0           | Systemic                | CT           |
| 6   | 66          | 1.24        | 163                 | 319                 | 0           | 0           | 0           | Wait and see             | No target for biopsy |
| 7   | 68          | 1.3         | 139                 | 349                 | 0           | 1           | 0           | Surgery                 | 1 LN histologically confirmed |
| 8   | 80          | 1.2         | 127                 | 216                 | 0           | 0           | 0           | Wait and see             | No target for biopsy |
| 9   | 72          | 0.17        | 74                  | 310                 | 0           | 0           | 0           | Core biopsy of prostate | n.a.         |
| 10  | 68          | 1.2         | 110                 | 240                 | 1           | 0           | 0           | RT or surgery            | n.a.         |
| 11  | 60          | 2.04        | 95                  | 280                 | 0           | 1           | 0           | Systemic                | CT (bone)    |
| 12  | 74          | 3.87        | 64                  | 360                 | 0           | 5           | 0           | Wait and see             | No target for biopsy |
| 13  | 51          | 0.4         | 140                 | 232                 | 0           | 0           | 0           | RT or surgery            | n.a.         |
| 14  | 54          | 10          | 187                 | 297                 | 0           | 2           | 0           |                         |              |

LN lymph node, LR local relapse, n.a. not available, RT radiotherapy, [68Ga]Ga-PSMA-HBED-CC PET/CT, [18F]PSMA [18F]DCFPyL PET/CT
Fig. 1 Patient no. 12 with a rising PSA level of 3.87 ng/ml. In the past, the patient had retroperitoneal lymph node metastases, which were irradiated. On a Biograph mCT 128 scanner, comparison between a MIP (maximum intensity projection) with $^{[18F]}$DCFPyL and b MIP with $^{[68Ga]}$Ga-PSMA-HBED-CC. $^{[18F]}$DCFPyL PET/CT clearly demonstrates several additional supradiaphragmatic PSMA-positive lesions. $^{[68Ga]}$Ga-PSMA-HBED-CC PET/CT showed the supradiaphragmal lesion in the sternum.

Fig. 2 Patient no. 12, Biograph mCT 128. $^{[18F]}$DCFPyL PET/CT (b) was suspicious of an additional lymph node metastasis in the dorsal mediastinum, visible as a normal-sized lymph node in a low-dose CT scan without tracer accumulation on c $^{[68Ga]}$Ga-PSMA-HBED-CC PET/CT. d Low-dose CT in bone window and e $^{[18F]}$DCFPyL PET/CT were suspicious of a bone metastasis in vertebra Th3, barely detectable in f $^{[68Ga]}$Ga-PSMA-HBED-CC PET/CT. h $^{[18F]}$DCFPyL PET/CT was clearly suspicious of bone metastasis in the processus xiphoideus sterni, hard to detect in g low-dose CT or i $^{[68Ga]}$Ga-PSMA-HBED-CC PET/CT.
sternal processus xiphoideus in a patient with concordant PSMA-positive retroperitoneal lymph node metastases (patient 12).

Verification of Lesions

The bone metastases in the lumbar vertebra L2 (patient 2) and in the thoracal vertebral Th3 (patient 12) were confirmed by CT retrospectively. In patient 7, a concordant left iliac PSMA-positive lymph node was detected with both tracers and an additional F-18 PSMA-positive pelvic lymph was reported. This patient underwent surgical lymph node resection, and the left iliac metastasis was confirmed histologically. The additional pelvic metastasis was not detected by salvage lymph node dissection, but PSA remained increased postoperatively, indicating that this lesion may have represented the remaining PSA-producing tissue. In 1 patient, the solitary PSMA spot in the irradiated prostate, seen in the [68Ga]Ga-PSMA-HBED-CC PET/CT and in the [18F]DCFPyL PET/CT, was not confirmed by core biopsy (patient 4). In 1 patient, the concordant solitary PSMA-avid lymph node metastasis was confirmed histologically by systematic lymphadenectomy, while core biopsy was negative for local relapse despite a focal PSMA concentration within the irradiated prostate (patient 1). Examples of the PSMA-positive lesions are shown in Figs. 1, 2, 3, and 4.

Quantitative Comparison

The mean SUV\textsubscript{max} in the concordant PSMA-positive lesions was 14.5 for [18F]DCFPyL and 12.2 for [68Ga]Ga-PSMA-HBED-CC (\(p=0.028\), \(n=15\) metastases). The mean background SUV\textsubscript{mean} values for [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC in all 14 patients examined were 6.2 and 5.1 in the liver (\(p=0.049\)), 4.9 and 7.2 in the spleen (\(p=0.005\)), 19.6 and 31.7 in the kidney (\(p=0.001\)), 1.3 and 1.2 in the mediastinum (\(p=0.056\), n.s.), and 10.9 and 12.9 in the parotid (\(n=0.121\), n.s.), respectively.

To compare the tumor/background contrast between the two tracers, we calculated SUV values in suspicious lesions/background in seven patients with maximum three lesions, detectable with both PET procedures. This resulted in a comparison of altogether 15 tumor/background ratios. Most of the suspected lymph node/bone metastases showed a higher SUV ratio for [18F]DCFPyL using the kidney (Fig. 5a) or the spleen as a reference region, but no significant difference was found when using for the liver (Fig. 5b) or the mediastinum as reference organ. In detail, the mean tumor to background ratios between the SUV\textsubscript{max} in the PSMA-avid lesions with [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC were 2.9 and 2.3 as compared with the SUV\textsubscript{mean} in the liver (\(p=0.167\), n.s.), 4.3 and 2.1 as compared with the SUV\textsubscript{mean} in the spleen (\(p=0.002\)), 1.0 and 0.4 as compared with the SUV\textsubscript{mean} in the kidney (\(p=0.006\)), 10.7 and 9.7 as compared with the SUV\textsubscript{mean} in the mediastinum (\(p=0.363\), n.s.), and 1.4 and 0.9 as compared with the SUV\textsubscript{mean} in the parotid (\(p=0.008\)), respectively.

Clinical Consequences

In the majority of cases, [68Ga]Ga-PSMA-HBED-CC and [18F]DCFPyL PET/CT resulted in accumulating evidence, supporting further treatment decisions consistently. Both imaging series accordingly supported decisions towards core biopsy of the irradiated prostate in three patients, to local therapy options (lymph node dissection or radiotherapy) in four patients with one to two PSMA-positive lymph nodes and to systematic therapy in three patients. In four patients, neither imaging test detected a lesion explaining the rise in PSA levels.
[18F]DCFPyL PET/CT resulted in the detection of additional vertebral bone metastases in two patients (patient 2 and 12) in an oligometastatic state (patient 2 showed bone metastases also in [68Ga]Ga-PSMA-HBED-CC PET/CT but to a lesser extent). This finding did not have immediate therapeutical consequences because both patients were asymptomatic at the time of their PET/CT examination. However, more accurate knowledge on the extent of bone metastases bears the potential to perform better targeted radiotherapy in the future (i.e., if the patients become symptomatic from their bone metastases). The detection of many PSMA-positive supradiaphragmatic lymph nodes with [18F]DCFPyL in addition to retroperitoneal lymph node metastases also detected with [68Ga]Ga-PSMA-HBED-CC supported the decision to omit local radiotherapy of the retroperitoneal lymphatic pathways (patient 12). In one patient, a second PSMA-avid lymph node in the upper pelvis was detected with [18F]DCFPyL in addition to another pelvic lymph node (detected with both tracers). In this patient, systematic bilateral pelvic lymph node dissection was performed and not influenced by the [18F]DCFPyL findings. Unfortunately, only the larger metastasis (positive with both tracers) was detected intraoperatively and the patient remained PSA positive after surgery (patient 7).

Discussion

We analyzed 14 patients who underwent both [68Ga]Ga-PSMA-HBED-CC PET/CT and [18F]DCFPyL PET/CT. In all cases, a rising PSA level indicated disease recurrence following prior treatment of prostate cancer.

The following findings emerge from this analysis:

- All suspicious lesions identified with [68Ga]Ga-PSMA-HBED-CC were detected with [18F]DCFPyL consistently.
- [18F]DCFPyL demonstrated a significantly higher SUVmax as compared to [68Ga]Ga-PSMA-HBED-CC in consistent lesions and a better tumor to background ratio when the kidney, spleen, or parotid was used as a reference organ. The tumor to background ratio did not differ significantly between [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC when the liver or the mediastinum was used as a reference organ. Although based on a small number of subjects, these findings support the notion that [18F]DCFPyL provides at least comparable tumor/background contrast as observed with [68Ga]Ga-PSMA-HBED-CC.
- Using [18F]DCFPyL, additional suspicious lesions plausible for further metastases were detected in 3/14 patients. This indicates a high sensitivity of this tracer.
One explanation for the higher detection rate using $^{18}$FDCFPyL can be found in the higher injected dose, which allowed later acquisition times, potentially leading to better signal to noise ratios due to reduction of nonspecific signal. Lower background activity has been observed for the $^{18}$FDCFPyL in some organs such as the kidney. Independently from injected dose, faster clearance of the tracer from non-target tissue and higher affinity, may potentially have contributed to the detection of additional skeletal metastases observed for $^{18}$FDCFPyL as compared to $^{68}$Ga-Ga-PSMA-HBED-CC.

It is important to notice that the higher detection rate for PSMA-avid lymph nodes by $^{18}$FDCFPyL was not attributed to retroperitoneal PSMA foci, where the differentiation against celiac ganglia (i.e., false-positive findings) might be a question [15].

Radiolabeling with Ga-68 is an excellent alternative for imaging centers with expertise in handling the commercially available $^{68}$Ge/$^{68}$Ga radionuclide generator but without own (cost-intensive) cyclotron. However, a single preparation (0.3–0.6 GBq Ga-68) may only allow scanning up to two to four patients and the output depends on the half-life of the generator. As now established at our center, a single radiolabeling procedure of $^{18}$FDCFPyL resulted in a batch containing 6 to 7 GBq of $^{18}$FDCFPyL. This rendered it possible to examine six patients after a single preparation with an optimal dose, which represents an advantage for
centers with an own cyclotron and a production of F-18 in the daily management. Furthermore, due to the longer half-life of F-18 (110 vs. 68 min for Ga-68), it may also allow transportation to remote sites from commercial vendors.

A limitation of the current study is the lack of a consistent histological validation of [18F]DCFPyL findings. In principle, it cannot be excluded that additional lesions detected with [18F]DCFPyL may represent false-positive findings. However, particularly small PSMA-positive findings cannot be easily confirmed histopathologically, and it is impossible to assess all lesions in patients with multiple metastases. Generally, good correspondence between [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC findings was observed, several lesions were confirmed histopathologically, and the additional bone lesions detected with [18F]DCFPyL were verified retrospectively by CT findings suspicious for bone metastases. Thus, we believe that the high sensitivity of [18F]DCFPyL, as indicated in the current study, appears plausible. Nevertheless, the findings of the current study are to be considered preliminary and the clinical performance of [18F]DCFPyL will have to be further analyzed in the future.

Another limitation can be found in the selection of patients. We did not recruit patients for both imaging series prospectively, and the selected population cannot serve as a representative sample. Due to the selection of patients with complex clinical questions (several of them being negative in [68Ga]Ga-PSMA-HBED-CC PET/CT), it might be possible that the diagnostic accuracy of [68Ga]Ga-PSMA-HBED-CC PET/CT is underestimated.

Comparison of the two tracers has not been carried out under identical conditions, i.e., mean injected dose and start of acquisition have been higher respectively later for [18F]DCFPyL, as compared to [68Ga]Ga-PSMA-HBED-CC PET/CT. It cannot be excluded that the performance of [68Ga]Ga-PSMA-HBED-CC PET/CT would have been more similar to [18F]DCFPyL under more identical examination conditions. However, it was the aim of this study to compare the two tracers under the circumstances usually available in clinical application. Generally, lower doses and earlier acquisition periods p.i. are selected for 68Ga-labeled tracers. The time period of 1 h between injection of [68Ga]Ga-PSMA-HBED-CC and the start of PET/CT was reported by many publications [2–5].

It was beyond the scope of an observational study to show time-activity curves. The time period of 2 h between the injection of [18F]DCFPyL and the start of data acquisition was chosen in the light of conventional receptor imaging in nuclear medicine using other tracers with contrast enhancement on delayed images and in accord with the data including time-activity curves published by Szabo and colleagues [14]. Szabo et al. have performed PET imaging at five different time points and demonstrated a small number of lesions which became visible only on PET-5 131–167 min p.i. The authors recommended delayed imaging at 2 h [14]. We have not tested different time periods between the injection of [18F]DCFPyL and the start of data acquisition.

Independently from the radiolabeling with [18F] or [68Ga], previous cancer therapies and low PSMA expression caused by tumor heterogeneity [16, 17] might be responsible for false-negative PET/CT results in some patients. We have learned from other studies that imaging of the choline transport and phosphorylation may detect PSMA-negative metastases in some cases [2, 3]. Future studies should investigate the diagnostic accuracy of F-18- or Ga-68-labeled PSMA in the early PSA-relapse <1 ng/ml, when [1C] or [18F] choline have low detection rates [18, 19] and should redefine the therapeutic impact of PET/CT [20–22]. Improved diagnostic accuracy should be confirmed by systematic comparison of sensitivity and specificity of both agents.

Conclusion

Our results indicate that the [18F]-labeled compound [18F]DCFPyL is a highly promising alternative to [68Ga]-Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer. Based on significantly higher SUV values in the PSMA-avid lesions, [18F]DCFPyL PET/CT may represent a valuable tool to detect small prostate cancer lesions with high sensitivity.

Conflict of Interest.

The authors declare that they have no competing interests.

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85
2. Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486–495
3. Afshar-Oromieh A, Zeichmann CM, Malcher A et al (2014) Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41(11):1–20
4. Afshar-Oromieh A, Haberkorn U, Schlemmer HP et al (2014) Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 41(5):887–897
5. Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209
6. Kratochwil C, Giesel FL, Eder M et al (2015) 177Lu-Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-014-2978-1
7. Zeichmann CM, Afshar-Oromieh A, Armor T et al (2014) Radiation dosimetry and first therapy results with a 224Th-labelled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 41:1280–1292
8. Chang SS, Reuter VE, Heston WDM et al (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA
expression in tumor-associated neovasculature. Cancer Res 59:3192–3198
9. Haffner MC, Kronberger IE, Ross JS et al (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancer. Human Pathol 40:1754–1761
10. Chen Y, Pullambhatla M, Foss CA et al (2011) 2-(2-(1-Carboxy-5-[(6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 17(24):7645–7653
11. Eder M, Schäfer M, Bauder-Wüst U et al (2012) (68) Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688–697
12. Schäfer M, Bauder-Wüst U, Leotta K et al (2012) A dimerized urea-based inhibitor of the prostate-specific membrane antigen for [68Ga]-PET imaging of prostate cancer. EJNMMI Res 2:23
13. Eder M, Neels O, Müller M et al (2014) Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals 7:777–796
14. Szabó Z, Mena E, Rowe SP et al (2015) Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. doi:10.1007/s11307-015-0850-8
15. Krohn T, Verburg FA, Pufe T et al (2015) [68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging 42:210–214
16. Mannweiler S, Amersdorfer P, Trajanoski S et al (2009) Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 15:167–172
17. Bostwick DG, Pacelli A, Blute M et al (1998) Prostate specific membrane antigen expression in prostate intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261
18. Castellucci P, Fuccio C, Rubello D et al (2011) Is there a role for [11C]-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 38:55–63
19. Graute V, Jansen N, Ubleis C et al (2012) Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 39:271–281
20. Rigatti P, Suardi N, Briganti A et al (2011) Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C] choline PET/CT. Eur Urol 60:935–943
21. Souvatzoglou M, Krause BJ, Pürschel A et al (2011) Influence of [11C]-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol 99:193–200
22. Würschmidt F, Petersen C, Wahl A et al (2011) [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiation. Oncology 6:44